Tag - IMNN

Developments

IMUNON’s Phase 2 data shows OS increase in women with advanced ovarian cancer

IMUNON (NASDAQ: IMNN) has announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy (N/ACT) showing...

March 25, 2026

Feature

IMUNON harmonizing life’s blueprint with immune system through DNA-based therapies

IMUNON (NASDAQ:IMNN) is advancing a distinctive approach to treating of some of the world’s most challenging diseases, leveraging a portfolio of proprietary immunology and DNA-based platforms that harness the body’s...

January 7, 2025

Tag - IMNN

IMUNON’s Phase 2 data shows OS increase in women with advanced ovarian cancer

IMUNON harmonizing life’s blueprint with immune system through DNA-based therapies

Subscribe